The mortality-to-incidence ratio initially increased in the early 2000s, declined sharply between 2008 and 2011, and remained stable thereafter.
Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction ...
The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
At a data cut-off of 37.3 months, EFS improved to 3.4 months for crenolanib, compared with 0.0 months for placebo.
The RAINIER study continues to enroll patients across additional dose levels. Mipletamig's design leverages Aptevo's ADAPTIR (TM) platform to deliver targeted T-cell engagement with the goal of ...
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31 ...
PRESS RELEASEAB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A ...
OS for Black patients was 57.8 months in those with a favorable ELN cytogenic RS, 14.2 months for those with intermediate RS ...
Black race is an independent prognostic factor for shorter survival in acute myeloid leukemia independent of cytogenetic ...
Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback